Leads Biolabs’ LBL-034 gets approval for multiple myeloma trial in humans
The company’s first-in-human investigational new drug applications to hold a single-arm, multicenter, open-label, dose-escalation, and expansion clinical study…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Jul 23
The company’s first-in-human investigational new drug applications to hold a single-arm, multicenter, open-label, dose-escalation, and expansion clinical study…
31 Jul 23
Daewoong Pharmaceutical, "Expecting the smooth approval with the successful phase 3 clinical trial in China aiming to reach…
25 Jul 23
First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ)…
19 Jul 23
First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication
13 Jul 23
The collaboration aims to assess the safety and effectiveness of BBP-398, an investigational SHP2 inhibitor developed by LianBio,…
13 Jul 23
Study aims to create the most robust, multi-omic dataset for patients with NSCLC
12 Jul 23
The decision was made by the firm after consultation with the data monitoring committee regarding results data from…
28 Jun 23
Topline results from the follicular lymphoma cohort demonstrated an ORR of 82%, which surpassed the protocol prespecified threshold…
23 Jun 23
Through the continued partnership, individuals affected by rare blood cancers, including various types of leukaemia, lymphoma, and myeloma,…
15 Jun 23
The collaboration involves combining Cullgen's uSMITE targeted protein degradation platform, which utilises novel E3 ligands, with Astellas' expertise…